Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease

Leukemia. 2006 Jan;20(1):172-3. doi: 10.1038/sj.leu.2403996.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Fatal Outcome
  • Female
  • Graft vs Host Disease / complications
  • Graft vs Host Disease / drug therapy*
  • Graft vs Host Disease / pathology
  • Humans
  • Male
  • Risk Factors
  • Rituximab
  • Scleroderma, Systemic / complications
  • Scleroderma, Systemic / drug therapy*
  • Scleroderma, Systemic / pathology
  • Steroids / therapeutic use*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Steroids
  • Rituximab